A
Amanda L. Christie
Researcher at Harvard University
Publications - 50
Citations - 7580
Amanda L. Christie is an academic researcher from Harvard University. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 29, co-authored 49 publications receiving 6415 citations. Previous affiliations of Amanda L. Christie include AstraZeneca & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Oliver Weigert,Andrew A. Lane,Liat Bird,Nadja Kopp,Bjoern Chapuy,Diederik van Bodegom,Angela V. Toms,Sachie Marubayashi,Amanda L. Christie,Michael R. McKeown,Ronald M. Paranal,James E. Bradner,Akinori Yoda,Christoph Gaul,Eric Vangrevelinghe,Vincent Romanet,Masato Murakami,Ralph Tiedt,Nicolas Ebel,Emeline Evrot,Alain De Pover,Catherine H. Régnier,Dirk Erdmann,Francesco Hofmann,Michael J. Eck,Stephen E. Sallan,Ross L. Levine,Andrew L. Kung,Fabienne Baffert,Thomas Radimerski,David M. Weinstock +30 more
TL;DR: Hsp90 inhibition in B cell acute lymphoblastic leukemia overcomes resistance to JAK2 inhibitors and induces apoptotic cell death in mice treated with these inhibitors.
Journal ArticleDOI
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
Ellen Weisberg,Abdel Kareem Azab,Paul W. Manley,Andrew L. Kung,Amanda L. Christie,Rod Bronson,Irene M. Ghobrial,James D. Griffin +7 more
TL;DR: The results support the idea of using CXCR4 inhibition in conjunction with targeted tyrosine kinase inhibition to override drug resistance in CML and suppress or eradicate residual disease.
Journal ArticleDOI
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Ellen Weisberg,Arghya Ray,Rosemary Barrett,Erik Nelson,Amanda L. Christie,Dale Porter,Christopher Sean Straub,Leigh Zawel,John F. Daley,Suzan Lazo-Kallanian,Richard Stone,Ilene Galinsky,David A. Frank,Andrew L. Kung,James D. Griffin +14 more
TL;DR: The results support the idea of using IAP inhibitors in conjunction with targeted tyrosine kinase inhibition to override drug resistance and suppress or eradicate residual disease.
Journal ArticleDOI
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations
Erik A. Nelson,Sarah R. Walker,Michael Xiang,Ellen Weisberg,Michal Bar-Natan,Rosemary Barrett,Suiyang Liu,Surender Kharbanda,Amanda L. Christie,Maria Nicolais,James D. Griffin,Richard Stone,Andrew L. Kung,David A. Frank +13 more
TL;DR: Pimozide reduces the tumor burden in a mouse model of FLT3-driven AML and may provide a new avenue for the treatment of AML, and these may be effective alone or in combination with tyrosine kinase inhibitors.
Journal ArticleDOI
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Shuo-Chieh Wu,Loretta S. Li,Nadja Kopp,Joan Montero,Bjoern Chapuy,Akinori Yoda,Amanda L. Christie,Huiyun Liu,Alexandra N. Christodoulou,Diederik van Bodegom,Jordy C.G. Van Der Zwet,Jacob V. Layer,Trevor Tivey,Andrew A. Lane,Jeremy Ryan,Samuel Y. Ng,Daniel J. DeAngelo,Richard Stone,David P. Steensma,Martha Wadleigh,Marian H. Harris,Emeline Mandon,Nicolas Ebel,Rita Andraos,Vincent Romanet,Arno Dölemeyer,Dario Sterker,Michael Zender,Scott J. Rodig,Masato Murakami,Francesco Hofmann,Frank C. Kuo,Michael J. Eck,Lewis B. Silverman,Stephen E. Sallan,Anthony Letai,Fabienne Baffert,Eric Vangrevelinghe,Thomas Radimerski,Christoph Gaul,David M. Weinstock,David M. Weinstock +41 more
TL;DR: CHZ868 potently suppressed the growth of CRLF2-rearranged human B-all cells, abrogated JAK2 signaling, and improved survival in mice with human or murine B-ALL, and these data support the testing of type II Jak2 inhibition in patients with JAK1-dependent leukemias and other disorders.